Readystate Asset Management LP Sells 288,480 Shares of Celldex Therapeutics, Inc. $CLDX
Readystate Asset Management LP significantly reduced its stake in Celldex Therapeutics Inc. by selling 288,480 shares, an 86.1% decrease, during the third quarter, retaining 46,520 shares valued at approximately $1.2 million. Despite this sale, analyst sentiment for Celldex Therapeutics is generally positive, with a "Moderate Buy" consensus and an average price target of $41.56, though ratings vary. The biopharmaceutical company focusing on immunotherapies for cancer is currently trading around $23, with a market capitalization of $1.53 billion.
Celldex Therapeutics (CLDX) Expected to Announce Earnings on Thursday
Celldex Therapeutics (CLDX) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts anticipating a loss of ($1.00) per share and revenue of $1.533 million. The company's stock opened at $23.00, trading within a 52-week range of $14.40 to $30.50, and holds a "Moderate Buy" consensus rating from analysts with an average price target of $41.56, despite some divergent views from firms like Barclays and Weiss. Institutional investors have also been active, with several increasing positions or buying new shares in CLDX during recent quarters.
Celldex to Present at Upcoming Investor Conferences
Celldex announced that its management will participate in three upcoming investor conferences in February and March 2026. The company will present at the Guggenheim Emerging Outlook: Biotech Summit, TD Cowen 46th Annual Health Care Conference, and Leerink Global Healthcare Conference. Live webcasts and replays of these presentations will be available on the Celldex website.
Celldex Therapeutics Teases Key Barzolvolimab Phase 3 Updates, New Data at Guggenheim Summit
Celldex Therapeutics outlined upcoming clinical milestones for its drug barzolvolimab, including Phase 3 updates for chronic spontaneous urticaria (CSU) trials, which are expected to complete accrual by summer 2026. The company also provided updates on its bispecific program CDX-622 and robust long-term CSU data showing significant efficacy and manageable safety. Celldex has enough cash to fund operations through 2027 but will require additional capital for a potential launch.
Top Picks 2026: Celldex Therapeutics Inc. (CLDX)
Celldex Therapeutics Inc. (CLDX) is recommended as a conservative biotech top pick for 2026 due to its lead compound, barzolvolimab ("barzo"), which has initiated a second Phase III study for chronic inducible urticaria (CIndU). Analysts believe barzo has blockbuster potential, with future indications likely to include food allergies, building on strong efficacy data and potential premium pricing. The drug is expected to drive higher stock target prices as its market value becomes more apparent.
Biotech Celldex to field investor questions at 3 conferences
Celldex (NASDAQ:CLDX) announced that its management will participate in three upcoming investor conferences in February and March 2026. These include the Guggenheim Emerging Outlook: Biotech Summit, TD Cowen Health Care Conference, and Leerink Global Healthcare Conference, all of which will feature live webcasts and 90-day replays for interested investors. The company will use these platforms to engage with investors regarding its advancements in immunology and antibody-based therapies.
Celldex to Present at Upcoming Investor Conferences
Celldex Therapeutics, Inc. announced its management will participate in fireside chats at three upcoming investor conferences in February and March 2026. These include the Guggenheim Emerging Outlook: Biotech Summit, TD Cowen 46th Annual Health Care Conference, and Leerink Global Healthcare Conference. Live webcasts and replays of the presentations will be available on the investor section of Celldex's website.
Celldex to Present at Upcoming Investor Conferences
Celldex announced that its management will participate in three upcoming investor conferences in February and March 2026. The company will hold fireside chats at the Guggenheim Emerging Outlook: Biotech Summit, TD Cowen 46th Annual Health Care Conference, and Leerink Global Healthcare Conference. Live webcasts and replays of these presentations will be available on the Celldex website.
Celldex to Present at Upcoming Investor Conferences
Celldex (NASDAQ:CLDX) announced that its management will participate in fireside chats at three upcoming investor conferences in February and March 2026. These include the Guggenheim Emerging Outlook: Biotech Summit, TD Cowen 46th Annual Health Care Conference, and Leerink Global Healthcare Conference. Live webcasts of these presentations will be accessible on the company's website, with replays available for 90 days.
Celldex Therapeutics Breaks Below 200-Day Moving Average - Notable for CLDX
Celldex Therapeutics, Inc. (CLDX) shares have fallen below their 200-day moving average of $23.76, trading as low as $23.61 on Thursday. The stock is currently down about 1.7% for the day. This movement is notable given its 52-week range of $14.40 to $30.50.
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum And Ongoing Losses
Celldex Therapeutics (CLDX) has seen recent share price momentum, closing at US$25.17, with a 30-day return of 6.81% and a one-year return of 8.73%. Despite reporting annual revenue of US$2.599 million and a significant loss of US$224.532 million, Simply Wall St's discounted cash flow (DCF) model suggests a fair value of $82.65 per share, indicating it may be undervalued. The company trades at a Price-to-Book ratio of 2.8x, which is below its selected peer average but slightly above the broader US biotech average, raising questions about whether the market is already pricing in future growth.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $41.56. Despite this positive outlook from analysts, the company reported an EPS miss of ($1.01) against an expected ($0.88) and has seen mixed insider and institutional activity. Notably, one insider sold a significant portion of shares, while major institutional investors increased their holdings.
Is Celldex Therapeutics (CLDX) Pricing Reflect Its DCF Upside After Mixed Multi‑Year Returns
This article analyzes Celldex Therapeutics (CLDX) stock valuation using Discounted Cash Flow (DCF) and Price-to-Book (P/B) ratios. The DCF model suggests CLDX is significantly undervalued by 68.9% at its current price of US$26.23, with an intrinsic value of US$84.42 per share. Conversely, the P/B ratio indicates the stock is priced "about right" when compared to biotech industry averages and a model-driven "Fair Ratio."
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness
Celldex Therapeutics (CLDX) has experienced a recent decline in share price, prompting an analysis of its valuation. While the company is still loss-making with significant net losses, its Price-to-Book ratio of 2.9x is slightly above the industry average but cheaper than its peer group. A Discounted Cash Flow (DCF) model suggests the shares are significantly undervalued at US$25.92, trading about 69% below an estimated future cash flow value of US$83.54, despite clinical and regulatory uncertainties.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Large Growth in Short Interest
Celldex Therapeutics (NASDAQ:CLDX) experienced a 20.1% increase in short interest during December, reaching 8,244,450 shares, which represents 13.0% of the float and a 12.3-day short-interest ratio. The company reported a Q4 EPS of ($1.01), missing analyst estimates, and has negative profitability measures, with analysts forecasting (-2.48) EPS for the current fiscal year. Despite an insider selling a significant portion of their shares, several hedge funds increased their holdings, and the stock carries a "Moderate Buy" consensus rating with a $44.10 price target.
Reassessing Celldex Therapeutics (CLDX) Valuation As Shares Trade At A Discount To DCF Estimates
Celldex Therapeutics (CLDX) shares, currently at US$27.38, appear undervalued according to a Discounted Cash Flow (DCF) model which estimates a fair value of US$84.70. While the company's Price-to-Book ratio of 3x is seen as good value compared to some peers, it is higher than the broader US biotech industry average. Investors are reassessing the clinical-stage pipeline and recent performance, but long clinical timelines and a significant net loss of US$224.532 million present ongoing risks.
How Advancing Antibody Pipeline And 2027 Cash Runway At Celldex Therapeutics (CLDX) Has Changed Its Investment Story
Celldex Therapeutics' investment narrative has been reshaped by the progression of its antibody pipeline, particularly the global Phase 3 trials for barzolvolimab and early-stage data for CDX-622. A significant factor is the extended cash runway through 2027, which supports the ongoing development of these key programs. While the company remains largely dependent on barzolvolimab's success, the new data reinforces the potential of its inflammatory disease pipeline.
Chronic Spontaneous Urticaria Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company
The Chronic Spontaneous Urticaria (CSU) market is expected to expand significantly, projected to reach approximately USD 7,555 million by 2034, growing at a CAGR of 15.9%. This growth is driven by increasing disease prevalence, awareness, and the introduction of emerging therapies from companies like Allakos, AstraZeneca, and Novartis. Key market developments include positive clinical trial data for briquilimab and remibrutinib, and FDA acceptance of Dupixent's resubmission for CSU treatment.
Is Celldex Therapeutics (CLDX) Pricing Reflect Its DCF Upside After Recent Share Swings
This article analyzes Celldex Therapeutics (CLDX) stock, suggesting it is undervalued by 67.3% according to a Discounted Cash Flow (DCF) analysis, with an estimated intrinsic value of US$84.97 per share compared to its current price of US$27.76. While its Price-to-Book ratio of 3.08x is above the industry average, a proprietary "Fair Ratio" is not available for a more precise P/B valuation. The article encourages investors to consider different "Narratives" based on their assumptions for future performance.
Chronic Spontaneous Urticaria Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company
The Chronic Spontaneous Urticaria (CSU) market is expected to grow significantly, reaching an estimated USD 7,555 million by 2034 across key markets, driven by rising disease awareness and emerging therapies. Promising clinical trial results for drugs like briquilimab and remibrutinib highlight rapid and effective disease control. Biologics currently dominate the treatment landscape, and several major pharmaceutical companies are actively developing new therapies for this condition.
Celldex Therapeutics Builds Momentum Around Barzolvolimab And Bispecific Antibody Programs
Celldex Therapeutics is gaining attention with its innovative antibody pipeline, particularly Barzolvolimab and CDX-622, which target severe allergic and inflammatory diseases. The company is advancing multiple Phase 3 and Phase 2 trials for Barzolvolimab in conditions like cold urticaria, symptomatic dermographism, chronic spontaneous urticaria, prurigo nodularis, and atopic dermatitis. Financially, Celldex reported a strong cash position of $583.2 million, sufficient to fund operations through 2027, despite increased net losses due to R&D spending.
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald
Cantor Fitzgerald reiterated its Overweight rating and $67.00 price target for Celldex Therapeutics (NASDAQ:CLDX), despite the company reporting a wider-than-expected Q3 2025 loss due to increased R&D expenses. Other analysts, like Stifel, have also reiterated Buy ratings as Celldex advances its barzolvolimab Phase 3 trials. The biopharmaceutical company is focused on developing therapeutic antibodies for inflammatory diseases and cancer.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Analysts
Celldex Therapeutics (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $44.10, despite missing recent EPS estimates and having negative profitability. Insider Richard M. Wright sold a significant portion of his holdings, while several institutional investors, including Vestal Point Capital and Wellington Management Group, substantially increased their positions in the biopharmaceutical company. Celldex, which focuses on targeted immunotherapies for cancer, currently trades around $26 with a market cap of $1.75 billion.
Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX
Simplify Asset Management Inc. recently invested $2.20 million in Celldex Therapeutics, acquiring 85,000 shares, representing 0.13% of the company. Celldex, a clinical-stage biopharmaceutical company, disappointed with a Q3 EPS miss and has negative margins, yet analysts assign a "Moderate Buy" rating with an average $44.10 price target. This comes despite an insider selling a significant portion of shares in November.
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21
Barclays has increased its price target for Celldex Therapeutics (CLDX) to $24 from $21, while reaffirming an Equal Weight rating. This adjustment is part of its 2026 outlook for the biotechnology sector. Concurrently, Celldex Therapeutics initiated a global Phase 3 trial for barzolvolimab, a specialized monoclonal antibody, to evaluate its efficacy and safety in treating cold urticaria and symptomatic dermographism.
Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX
Corient Private Wealth LLC recently acquired 201,717 shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the second quarter, valued at approximately $4.11 million. This makes Corient a significant new institutional holder of the biopharmaceutical company's stock, though other institutions like American Century Companies Inc. hold even larger stakes. Insider Richard M. Wright recently sold a substantial portion of his shares, while analysts have a "Moderate Buy" consensus rating with a $44.10 price target despite the company missing its last quarterly EPS estimate.
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21
Barclays has increased its price target for Celldex Therapeutics (CLDX) to $24 from $21, reaffirming an "Equal Weight" rating, considering its 2026 outlook for the biotechnology sector. The adjustment comes as Celldex initiated a global Phase 3 trial for barzolvolimab, a crucial drug for cold urticaria and symptomatic dermographism, which has shown promising results in earlier studies. Despite the potential, the article suggests that certain AI stocks might offer greater upside and less risk than CLDX.
Celldex Therapeutics (CLDX): Assessing Valuation After a Recent Share Price Uptick
Celldex Therapeutics (CLDX) has seen a recent uptick in its share price, prompting investors to assess its valuation. Despite the recent gains, potentially indicating improving momentum, the clinical-stage biotech faces a volatile history with a negative 3-year total shareholder return. The company's price-to-book ratio of 2.8x suggests it's modestly valued compared to some peers but slightly expensive relative to the broader US biotech industry, reflecting ongoing risks such as trial setbacks and potential dilution.
Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $24.00 at Barclays
Barclays has increased its price target for Celldex Therapeutics (NASDAQ:CLDX) to $24.00, though it maintains an "underweight" rating, suggesting a potential 9.62% downside. This rating adjustment follows Celldex missing its Q3 earnings estimates and insider stock sales, even as the consensus analyst rating remains a "Moderate Buy" with an average target of $44.10. Other analysts have provided conflicting ratings, ranging from "Strong Buy" to "Sell," reflecting general mixed sentiment towards the biopharmaceutical company.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Brokerages
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month target price of $43.80. This sentiment comes despite the company missing Q3 earnings estimates and insider Richard M. Wright significantly reducing his stake. The stock is currently trading near its 12-month high.
TFG Asset Management GP Ltd Has $6.43 Million Stake in Celldex Therapeutics, Inc. $CLDX
TFG Asset Management GP Ltd has significantly increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 21.1%, now owning 316,150 shares valued at approximately $6.43 million. This makes Celldex its 15th largest holding, and the company currently holds a "Moderate Buy" rating from analysts with an average target price of $43.80, despite recent insider share sales and a quarterly earnings miss.
Eventide Asset Management LLC Lowers Stake in Celldex Therapeutics, Inc. $CLDX
Eventide Asset Management LLC significantly reduced its stake in Celldex Therapeutics (NASDAQ:CLDX) by 63.9% in Q2, selling over 2.3 million shares and retaining 1.3 million. This comes as insider Richard M. Wright also sold a substantial portion of his holdings. Despite these sales and negative earnings, analysts maintain a "Moderate Buy" rating with an average price target of $43.80.
Bellevue Group AG Has $67.31 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX
Bellevue Group AG significantly increased its stake in Celldex Therapeutics, Inc., now holding 3,307,569 shares valued at approximately $67.31 million, representing about 4.98% of the company. Despite an insider sale by Richard M. Wright, analysts maintain a "Moderate Buy" consensus rating with an average target price of $43.80 for Celldex Therapeutics. The company recently missed quarterly EPS expectations, reporting a loss of $1.01 per share against an estimated loss of $0.88.
Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors?
Celldex Therapeutics has initiated a global Phase 3 EMBARQ trial for barzolvolimab in patients with cold urticaria and symptomatic dermographism, marking its second late-stage program for the drug. While this expands the potential market for barzolvolimab, the investment narrative for Celldex still heavily relies on the success of its ongoing chronic spontaneous urticaria program and future updates from this new study, with sustained losses remaining a significant risk. The market has reacted positively to the Phase 3 initiation, but execution risks and funding for multiple programs pose challenges.
Celldex Therapeutics (CLDX) Valuation After Launching Second Global Phase 3 Program for Barzolvolimab
Celldex Therapeutics initiated a second global Phase 3 trial for barzolvolimab, following strong Phase 2 results. The company's stock has seen recent surges, leading to a valuation discussion centered on its price-to-book ratio of 3.3x, which analysts consider "about right" given the barzolvolimab opportunity. Investors are urged to consider potential clinical trial setbacks and cash burn as risks.
Celldex (NASDAQ: CLDX) begins Phase 3 ColdU, SD trial after positive Phase 2
Celldex (NASDAQ: CLDX) has initiated global Phase 3 trials (EMBARQ-ColdU and SD) for its drug barzolvolimab, targeting cold urticaria (ColdU) and symptomatic dermographism (SD). This follows successful Phase 2 results which showed rapid, durable responses and a well-tolerated safety profile. The Phase 3 program aims to enroll approximately 240 participants across 75 sites in 7 countries to further evaluate the drug's efficacy and safety.
Celldex Therapeutics Initiates Global Phase 3 Trial for Barzolvolimab in Cold Urticaria, Symptomatic Dermographism
Celldex Therapeutics has initiated a global Phase 3 clinical trial for its drug candidate Barzolvolimab, targeting chronic urticarias, specifically cold urticaria and symptomatic dermographism. Barzolvolimab is a monoclonal antibody designed to inhibit the KIT receptor, addressing mast cell-mediated diseases. This move follows previous positive data from Phase 2 studies, demonstrating the drug's effectiveness in providing complete urticaria control.
Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism
Celldex Therapeutics Inc. (CLDX) has initiated a global registrational Phase 3 program for its drug barzolvolimab, targeting cold urticaria and symptomatic dermographism. The company anticipates releasing data from the open-label extension of the study in the first quarter of 2026. This move signifies a significant advancement in the development of barzolvolimab for these dermatological conditions.
Celldex Initiates Global Registrational Phase 3 Program of
Celldex has initiated a global Phase 3 program (EMBARQ-ColdU and SD) for barzolvolimab, targeting adult patients with cold urticaria (ColdU) and symptomatic dermographism (SD) who remain symptomatic despite H1 antihistamine treatment. Barzolvolimab, a humanized monoclonal antibody, demonstrated significant clinical benefit in a Phase 2 study by inhibiting KIT, a receptor tyrosine kinase crucial for mast cell function, which drives these inflammatory diseases. The company aims to provide a much-needed advanced therapy for these conditions, which currently lack approved treatments beyond antihistamines and significantly impact patients' quality of life.
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
Celldex has initiated a global Phase 3 trial (EMBARQ-ColdU and SD) for barzolvolimab, targeting adult patients with cold urticaria (ColdU) and symptomatic dermographism (SD) who remain symptomatic despite H1 antihistamine treatment. This program aims to establish the drug's efficacy and safety, building on positive Phase 2 results that demonstrated rapid, sustained, and complete disease responses. There are currently no advanced therapies approved for ColdU and SD, conditions affecting over 533,000 patients in the US and Europe, highlighting the significant unmet medical need barzolvolimab seeks to address.
Celldex Therapeutics stock hits 52-week high at $29.14
Celldex Therapeutics Inc (CLDX) stock has reached a 52-week high of $29.14, demonstrating a 10.86% positive change over the past year, reflecting investor confidence. Despite this milestone, the company reported a larger-than-expected loss of $1.01 per share in its third-quarter earnings due to increased R&D expenses, while it continues to advance its Phase 3 trials for barzovolimab, with Stifel reiterating a Buy rating and a $58.00 price target. This momentum is closely watched by investors as Celldex progresses its therapeutic solutions.
Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX
Fisher Asset Management LLC reduced its stake in Celldex Therapeutics, Inc. by 5.7% in the second quarter of 2025, selling 49,420 shares and retaining 822,208 shares valued at $16.73 million. This comes as company insider Richard M. Wright also significantly decreased his holdings by over 70%. Despite some institutional buying and a "Moderate Buy" consensus from analysts with an average price target of $43.80, the company missed its recent quarterly EPS estimates.
American Century Companies Inc. Grows Position in Celldex Therapeutics, Inc. $CLDX
American Century Companies Inc. increased its stake in Celldex Therapeutics (NASDAQ:CLDX) by 24.7% in Q2, bringing their total ownership to 1.17% of the company. Other hedge funds also modified their positions in CLDX. Celldex Therapeutics reported a quarterly EPS miss and has an average analyst rating of "Moderate Buy" with an average price target of $43.80.
Segall Bryant & Hamill LLC Invests $7.89 Million in Celldex Therapeutics, Inc. $CLDX
Segall Bryant & Hamill LLC has invested $7.89 million in Celldex Therapeutics, Inc. by acquiring 387,888 shares, representing about 0.58% of the company. Celldex Therapeutics (NASDAQ:CLDX) currently holds a "Moderate Buy" consensus from analysts, with an average target price of $43.80, though some firms have adjusted targets or ratings. The biopharmaceutical company recently reported a quarterly EPS of -$1.01 and saw one insider, Richard M. Wright, sell a significant portion of shares.
Celldex Therapeutics (CLDX): Assessing Valuation After Recent Revenue Growth and Share Price Swings
Celldex Therapeutics (CLDX) has seen recent share price swings, with an 8% dip over the past month despite an almost 80% year-over-year revenue growth. The company is currently trading at a price-to-book ratio of 2.8x, which is above the US Biotech industry average but less aggressive than its peer average. Investors are balancing strong revenue growth against ongoing profit challenges and net losses, leading to a mixed valuation picture.
What Celldex Therapeutics (CLDX)'s Strong Barzolvolimab Data and Commercial Focus Mean for Shareholders
Celldex Therapeutics reported strong positive Phase 2 data for barzolvolimab in various urticaria forms, demonstrating rapid and sustained disease control and a favorable safety profile. The company has also appointed Teri Lawver as Chief Commercial Officer, signaling a strategic focus on commercializing its pipeline. While these developments are positive, Celldex remains unprofitable, and investors should monitor trial progress and cash utilization.
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Celldex has appointed Teri Lawver as Senior Vice President, Chief Commercial Officer, replacing the retiring Richard Wright. Ms. Lawver brings 30 years of global healthcare experience, including significant commercial launch and P&L leadership roles at companies like Johnson & Johnson and Dexcom. Her expertise in immunology and inflammation will be crucial as Celldex prepares for the potential launch of barzolvolimab and advances its pipeline.
Celldex Announces Initial Positive Results from Phase 1
Celldex (NASDAQ:CLDX) reported positive initial results from its Phase 1 study of CDX-622, a novel bispecific antibody targeting inflammation and fibrosis. The study in healthy volunteers demonstrated that CDX-622 was well-tolerated, exhibited a good pharmacokinetic profile, and led to rapid and sustained reductions in serum tryptase, indicating mast cell inhibition. These findings support further development of CDX-622 for inflammatory and fibrotic disorders.
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
Celldex announced positive initial results from the Phase 1 study of CDX-622, a novel bispecific antibody designed to target inflammation and fibrosis by mast cell depletion and TSLP neutralization. The study demonstrated that CDX-622 was well-tolerated, exhibited a good pharmacokinetic profile, and led to rapid and sustained reductions in serum tryptase, indicating effective mast cell inhibition. These findings support further development, with multiple ascending doses currently being tested and a Phase 1b study in asthma patients planned for the next year.
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
Celldex Therapeutics announced positive initial results from its Phase 1 trial of CDX-622, a bispecific antibody designed to target inflammation and fibrosis by depleting mast cells and neutralizing TSLP. The study showed that CDX-622 was well-tolerated, had a favorable pharmacokinetic profile, and led to sustained reductions in serum tryptase. These results support the continued development of CDX-622 for inflammatory and fibrotic disorders, with plans for a Phase 1b study in asthma patients.
